Objectives To investigate the extension of experimentally induced peri-implantitis lesions under various antiresorptive and antiangiogenic medications. Material and methods Fourty-eight albino rats had randomly received the following medications (dual application, n = 8 each): (1) amino-bisphosphonate (zoledronate) (Zo), (2) RANKL inhibitor (denosumab) (De), (3) antiangiogenic (bevacizumab) (Be), (4) Zo+Be, (5) De+Be, or (6) no medication (Co). Ligature- and lipopolysaccharide-induced peri-implantitis lesions were established at 2 maxillary implants over a period of 16 weeks. Histological (e.g., apical extension and surface area of the inflammatory cell infiltrate—aICT, ICT; defect length; defect width; CD68 positive cells) and bone micromorphometric (μCT) outcomes were assessed. The animal was defined as a statistical unit. Results A total of n = 38 animals (Zo = 6, De = 6, Be = 8, Zo + Be = 6, De + Be = 5, Co = 7) were analyzed. ICT’s were commonly marked by a positive CD68 antigen reactivity. Comparable median aICT (lowest—Zo: 0.53 mm; highest—Be: 1.22 mm), ICT (lowest—De + Be: 0.00 mm2; highest—Co: 0.49 mm2), defect length (lowest—Zo: 0.90 mm; highest—Co: 1.93 mm) and defect width (lowest—De+Be: 1.27 mm; highest—Be: 1.80 mm) values were noted in all test and control groups. Within an inner (diameter: 0.8 mm) cylindric volume of interest, the bone microstructure did not significantly differ between groups. Conclusions The present analysis did not reveal any marked effects of various antiresorptive/ antiangiogenic medications on the extension of experimentally induced peri-implantitis lesions. Clinical relevance The extension of peri-implantitis lesions may not be facilitated by the antiresorptive and antiangiogenic medications investigated.

Aim To evaluate the efficacy of different types of rehabilitation with fixed or removable full‐arch implant‐supported prosthesis designs in terms of implant loss and success in patients with at least one edentulous jaw, with tooth loss mainly due to periodontitis. Materials and methods Clinical studies with at least 12 months reporting on implant loss and implant success were searched. Meta‐analysis was conducted to estimate cumulative implant loss considering different prostheses designs. Results A total of 11 studies with unclear to low risk of bias were included in the analysis. Estimated cumulative implant loss for fixed prostheses within 1 year and 5 years was 0.64% (95% confidence interval [CI]: 0.31%–1.31%) and 1.85% (95% CI: 0.85%–3.95%), respectively. The corresponding values for removable prostheses amounted to 0.71% (95% CI: 0.22%–2.28%) and 4.45% (95% CI: 2.48%–7.85%). Peri‐implantitis affected 10%–50% of the patients restored with implant‐supported fixed prostheses. Conclusions Based on the limited low‐quality data, the present analysis points to a low and similar cumulative implant loss within 1 year for patients with tooth loss mainly due to stage IV periodontitis restored with either removable or fixed implant‐supported full‐arch prosthesis. At 5 years of functioning, there was a tendency for better outcomes using fixed designs.